|
 The cocktail, a combination of two antibodies casirivimab and
imdevimab, was authorized in November for emergency use by the U.S.
Food and Drug Administration.
Independent Data Monitoring Committee found that both 1,200mg and
2,400mg doses of the cocktail had reduced the rate of
hospitalization and deaths compared with placebo, according to the
company. The panel has recommended that Regeneron should stop
enrolling patients in the placebo group for its ongoing late-stage
trial.
The company plans to immediately follow the panel's recommendation
and also share details of unblinded data from the trial once it
becomes available in March.
[to top of second column] |
 The Regeneron treatment is part
of a class of drugs known as monoclonal
antibodies, which are manufactured copies of
antibodies created by the human body to fight
infections.
In January, the U.S. government said it will buy
1.25 million additional doses of Regeneron
Pharmaceuticals' COVID-19 antibody cocktail for
about $2.63 billion, bringing the total supply
of the treatment to more than 1.5 million doses.
(Reporting by Vishwadha Chander in Bengaluru,
Editing by Sherry Jacob-Phillips)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
